Why Credit Suisse Sees AnaptysBio Having 80% to 200% Upside
AnaptysBio has been called on to have as much as 82% upside in a Credit Suisse research report. There is a scenario in which the analyst even sees as much as 200% upside.
AnaptysBio has been called on to have as much as 82% upside in a Credit Suisse research report. There is a scenario in which the analyst even sees as much as 200% upside.
Cara shares jumped on Wednesday after the firm announced topline data from its late-stage trial in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus.
Goldman Sachs has muted any upside view by downgrading Gilead Sciences to Sell and lowering its price target.
Kezar Life Sciences shares were absolutely crushed on Tuesday after the firm revealed data from its midstage trial in patients with systemic lupus erythematosus.
The May 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
The May 15 short interest data have been compared with the previous report, and short interest in most of these selected biotech stocks increased.
New research discusses links between diet and cancer risk for Americans.
Despite the wearing down of hepatitis C drugs and the political climate targeting drug prices, this analyst sees stabilization and predictability in the base businesses of two key biotech leaders.
Tonix Pharmaceuticals shares jumped on Thursday after the firm announced that it has in-licensed a Phase 2 asset, TNX-1300 for the treatment of cocaine intoxication.
Eli Lilly has announced that its Insulin Lispro Injection is now available for order in pharmacies for people who use its rapid-acting insulin and need a lower-cost option.
Ocular Therapeutix shares took a beating on Tuesday after the firm announced late-stage results for patients with primary open-angle glaucoma or ocular hypertension. These results come from the Phase 3 clinical trial of OTX-TP,…
BioCryst Pharmaceuticals shares were absolutely crushed in Tuesday’s session after the company announced late-stage results for its study in hereditary angioedema patients.
New research indicates that caffeine may not be the reason that some coffee drinkers feel a need for a bowel movement after their morning coffee.
This is known as the world’s largest clinical cancer conference, and it always delivers new results on clinical trials and updated treatments in the field. Not to mention, this conference has the potential to…
If there is one former Dow Jones industrial average leader that is in need of serious help, look no further than General Electric.